FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to psychiatry and narcology, and concerns the treatment of addiction and impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors. For this purpose, a selective PDE7 inhibitor is administered in combination with a dopaminergic agent.
EFFECT: effective treatment of addiction is provided due to synergistic inhibition of activation of neurons of the dopaminergic ventral tectum area by substances causing addiction.
13 cl, 36 dwg, 10 ex
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2011 |
|
RU2661410C2 |
USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | 2010 |
|
RU2600869C2 |
MACROCYCLIC HEPATITIS TYPE C VIRUS INHIBITORS | 2006 |
|
RU2419619C2 |
PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
HEPATITIS C VIRUS MACROCYCLIC INHIBITORS | 2006 |
|
RU2486189C2 |
MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | 2006 |
|
RU2441870C2 |
PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
THERAPEUTICALLY ACTIVE DERIVATIVES OF OXAZOLINE | 2013 |
|
RU2656209C2 |
COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
Authors
Dates
2018-08-28—Published
2013-05-07—Filed